SAM-0022

SAM-0022 is a small molecule drug developed by Samsara Therapeutics. It acts as an inhibitor of peripheral myelin protein 22 (PMP22) and as a modulator of beclin-1, targeting pathways involved in autophagy and myelination. The primary indication for SAM-0022 is Charcot-Marie-Tooth Disease, Type Ia, a hereditary neuropathy characterized by demyelination of peripheral nerves. By inhibiting PMP22 and modulating beclin-1, the drug aims to improve autophagic processes and address underlying disease mechanisms in neurodegenerative and congenital nervous system disorders[1][3]. As of the latest update, SAM-0022 remains in preclinical development.